Comparative Pharmacology
Head-to-head clinical analysis: BEYAZ versus NATAZIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEYAZ versus NATAZIA.
BEYAZ vs NATAZIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.
One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.
Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Drospirenone: approximately 30 hours (terminal). Ethinyl estradiol: approximately 13-15 hours (terminal). Steady-state reached within 10 days. Clinical context: once-daily dosing maintains therapeutic levels with minimal accumulation after 3-4 cycles.
Terminal half-life approximately 30 hours for drospirenone and 24 hours for ethinyl estradiol; steady-state achieved within 8–10 days.
Urine (45-55% as metabolites), feces (30-40% as metabolites), with enterohepatic recirculation of ethinyl estradiol metabolites.
Fecal excretion is the primary route (approximately 68%), with renal excretion accounting for about 27% (mostly as metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive